Frequent genetic rearrangements in the androgen receptor could be limiting treatment options for prostate cancer patients, according to new research out of the University of Minnesota. Currently, the main treatment for prostate cancer inhibits androgen receptor activity. However, the new paper identified frequent rearrangements in the metastases of prostate cancer, allowing cancer cells to accumulate a variety of receptor forms and increasing resistance to treatments.
The paper is published in the latest issue of Nature Communications.
“We knew genetic rearrangements in the androgen receptor occurred in laboratory models of prostate cancer progression, and this could promote therapeutic resistance,” said Scott Dehm, Ph.D., associate professor in the Department of Laboratory Medicine and Pathology in the University of Minnesota Medical School and a member of the Masonic Cancer Center, University of Minnesota. “An outstanding question was if this reflected a mechanism of therapeutic resistance in prostate cancer patients, or whether it was unique to laboratory models.”